IntelGenx: IntelGenx begins patient dosing in phase 2 MONTPARK trial of Montelukast VersaFilm in patients with Parkinson's disease
IntelGenx Corp. announced that Montelukast VersaFilm has been administered to the first Parkinson's disease (PD) patients in the phase 2 ('MONTPARK') clinical trial.
Read full article »
IntelGenx is a Canada-based drug delivery company that develops novel oral thin film and transdermal drug products for pharmaceutical and animal health markets.
Read more